ArticleRwanda journal of medicine and health sciences2025
Risk Modelling and Seroprevalence of Dengue Virus Non-structural protein-1 Antigenemia and Antibodies among Febrile Patients in Ilorin, Nigeria.
Article in Rwanda journal of medicine and health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dengue fever is one of the global arboviral diseases posing significant health challenges, particularly in tropical and subtropical regions. However, there is limited data on the seroprevalence and risk factors of dengue virus infection among febrile patients in this region, and no studies have combined risk modelling and serological analysis for its disease surveillance. Objectives: This study determines the seroprevalence and risk analysis of Dengue Virus Non-structural protein 1 antigen and Immunoglobulin G and M antibodies among febrile patients in Ilorin, Nigeria. Methods: A cross-sectional study using a finite population correction (FPC) approach, where 182 blood samples were collected from consenting febrile patients and screened for DNV immunological markers. A structured questionnaire was used for socio-demographic and risk factors collation, while data analysis and Generalized Linear Model (GLM) were used for risk impact assessment on DNV outcome. Results: Prevalence of DNV NS1 antigen, IgG and IgM antibodies was 36% (66), 32% (62) and 16% (29), respectively. At 26 years mean age, the highest prevalence was recorded among female subjects, the employed groups and participants with formal education. The effect of age and gender was statistically significant at P<0.05, while occupation was not. The GLM presented the combined risk factors as strong predictors of DNV infection outcome at p (Slope=0) = 2.9259×10-9. Conclusions: High prevalence of dengue virus and significant association of risk factors was determined. Inclusion of DNV screening for febrile patients to reduce anti-malaria resistance is advocated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.